The State Council has released a second draft proposal outlining measures to support the high-quality development of innovative drugs through medical insurance reforms. The document emphasizes the establishment of innovative drug investment funds, self-assessment mechanisms for drug pricing, and enhanced real-world research support.<\/p>\n\n\n\n
Key Proposals<\/strong><\/p>\n\n\n\n NRDL and Drug Listing<\/strong> Tripartite Agreements<\/strong> Multi-Level Healthcare System<\/strong> Charitable Assistance and Overseas Expansion<\/strong><\/p>\n\n\n\n\n
The draft mandates direct online listing of drugs in the National Reimbursement Drug List (NRDL) and Class C drug list. Medical institutions must adjust their drug catalogs promptly or establish green channels for temporary procurement to meet clinical needs. By 2025, the medical insurance fund will directly settle expenses for NRDL and volume-based procurement (VBP) drugs, gradually expanding to all listed drugs.<\/p>\n\n\n\n
In regions with sufficient medical insurance fund balances, medical institutions, innovative drug companies, and healthcare security departments are supported to sign tripartite agreements. The medical insurance fund will prepay up to 80% of the expected annual expenses for innovative drugs within four years of their inclusion in the list, reducing corporate capital turnover pressure.<\/p>\n\n\n\n
The document highlights the acceleration of a multi-level medical security system, integrating basic medical insurance (BMI), commercial health insurance, and charitable assistance. It focuses on supporting commercial health insurance products that cover costs outside the BMI drug list, regardless of age or health status, with appropriate premiums.<\/p>\n\n\n\n